Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEL-212 vs Krystexxa in Refractory Gout
NCT03905512Phase 2Completed
- Sponsor
- Selecta Biosciences
- Start
- May 2019
- Primary completion
- Aug 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SEL-212 in gout (2 arms), sponsored by Selecta Biosciences. Primary endpoint: Number of Participants With Serum Uric Acid (SUA) Reduction of < 6 mg/dL for at Least 80% of the Time. Started May 2019; status: completed.
02
Drugs
SEL-212
03
Conditions
gout
Beyond the preview
Go deeper on NCT03905512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905512.